(Press-News.org) A new blood test could help emergency room doctors quickly diagnose traumatic brain injury and determine its severity. The findings, published July 10 in the Journal of Neurotrauma, could help identify patients who might benefit from extra therapy or experimental treatments.
"Compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes," says Frederick Korley, M.D., Ph.D., an assistant professor of emergency medicine at the Johns Hopkins University School of Medicine and first author of the new paper.
After a hit to the head or rapid whiplash, whether from a car crash, athletic event or other accident, millions of Americans develop traumatic brain injuries (TBIs) each year. TBIs can range from mild concussions -- causing only a headache or temporary blurred vision -- to much more severe injuries -- causing seizures, confusion, memory and attention problems, muscle weakness, or coma for many months. These symptoms, whether mild or more severe, are generally caused by damaged brain cells.
Until now, most physicians have relied on CT scans and patients' symptoms to determine whether to send them home and have them resume their usual activities or take extra precautions. However, CT scans can only detect bleeding in the brain, not damage to brain cells, which can happen without bleeding.
"A typical situation is that someone comes to the emergency department with a suspected TBI, we get a CT scan, and if the scan shows no bleeding, we send the patient home," says Korley. "However, these patients go home and continue having headaches, difficulty concentrating and memory problems, and they can't figure out why they are having these symptoms after doctors told them everything was fine."
Korley and collaborators around the country wanted to know if a blood test could better predict which patients would have ongoing brain injury-related problems, to provide better treatment for them. So they measured the levels of three proteins that they suspected play a role in brain cell activity in more than 300 patients with a TBI and 150 patients without brain injuries. Then, they followed those with a TBI for the next six months.
Levels of one protein, called brain-derived neurotrophic factor (BDNF), taken within 24 hours of someone's head injury, could predict the severity of a TBI and how a patient would fare, they found. While healthy people averaged 60 nanograms per milliliter of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 nanograms per milliliter, and those with the most severe TBIs had even lower levels, around 4 nanograms per milliliter. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later. But in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
"The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist," Korley says. In addition, it could help decide which patients to enroll in clinical trials for new drugs or therapies targeting severe TBIs.
Korley would like to follow up with more research on why, at a molecular level, brain injuries lower levels of BDNF in the blood and whether things known to increase BDNF levels -- including exercise and omega-3 fatty acids -- could help treat TBIs. He also wants to know whether changes in BDNF levels over time can be a proxy for recovery and if they could be used to gauge the effectiveness of an intervention.
"We looked at that very first blood sample obtained within 24 hours of an injury," he says. "But for BDNF to be used as a surrogate outcome, we'll have to see what happens to BDNF blood levels down the line, at one, three or six months after the injury." He and his collaborators have already started collecting data for those prospective studies, he adds.
INFORMATION:
Other authors on the paper are Haris I. Sair and Allen D. Everett of the Johns Hopkins University School of Medicine; Ramon Diaz-Arrastia of the Uniformed Services University of Health Sciences; Alan H.B. Wu of the San Francisco General Hospital; John K. Yue and Geoffrey T. Manley of the University of California, San Francisco; and Jennifer Van Eyk of Cedars-Sinai Medical Center.
Philadelphia, July 30, 2015 - In a new national survey of chronic obstructive pulmonary disease (COPD) patients, Health Union reveals a surprising lack of awareness of risk factors and knowledge of diagnosis stage among patients. Results demonstrate a severe impact on quality of life, employment, and ability to afford treatment.
COPD, the third most common cause of death in the United States, describes a group of lung conditions that severely impact the breathing of nearly 15 million people in the U.S. (or six percent of the population) and more than 65 million worldwide. ...
WASHINGTON, DC, July 28, 2015 -- Recent research has shown that racial segregation in the U.S. is declining between neighborhoods, but a new study indicates that segregation is manifesting itself in other ways -- not disappearing.
"We just can't get too excited by recent declines in neighborhood segregation," said lead author Daniel Lichter, the Ferris Family Professor in the Department of Policy Analysis and Management and a professor in the Department of Sociology at Cornell University. "The truth is neighborhood segregation still remains high in America, and our study ...
This news release is available in French. By blocking the expression of a certain gene in patients, University of Montreal researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their blood, even in various severe forms of hypertriglyceridemia and regardless of the base values or the treatment the patient usually receives. The gene in question codes for the apoC-III protein. "Our study suggests that the proteine apoC-III plays a key role in the management of triglycerides. Triglycerides, like cholesterol, are lipids. ...
URBANA, Ill. - With many types of cancers, early detection offers the best hope for survival. However, research into new early-detection screenings, as well as possible interventional radiology and surgical treatments, has been hindered by the lack of a large animal model that would accurately reflect the types of cancers seen in human cells.
For the last several years, researchers at the University of Illinois interested in improving screening programs for cancer have studied gene expression in mice, humans, and pigs in an effort to create a large-animal model that ...
Support for eliminating existing exemptions, except for medical reasons, from immunization laws was among the policy recommendations adopted last weekend at the summer meeting of the Board of Regents of the American College of Physicians (ACP).
"Allowing exemptions based on non-medical reasons poses a risk both to the unvaccinated person and to public health," said Wayne J. Riley, MD, MPH, MBA, MACP, president of ACP,
"Intentionally unvaccinated individuals can pose a danger to the public, especially to individuals who cannot be vaccinated for medical reasons."
The ...
A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital.
The drug, called vismodegib, is designed to block a key protein in the sonic hedgehog (SHH) signaling pathway. The pathway is normally active during fetal development and is inappropriately switched on in about 30 percent of medulloblastoma tumors, including about 60 percent of tumors ...
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell. The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function.
The artificial ribosome, called Ribo-T, was created in the laboratories of Alexander Mankin, director of the UIC College of Pharmacy's Center for Biomolecular Sciences, ...
It's one thing to grow bacteria in a test tube, perform a screen in the lab, and find a mutation in the pathogen's genes. It's a whole other thing, and much rarer, to find the exact same mutation in nature--in this case, in E. coli in urine samples from some 500 patients suffering from relapsing urinary tract infections.
The confluent discovery, by University Distinguished Professor Kim Lewis and his colleagues, was published on Wednesday in the journal Nature. It could put people with relapsing UTIs on the fast track for a new therapeutic regimen that Lewis described ...
RICHLAND, Wash. -- Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot -- and where. The model can also suggest the most effective way to reduce soot on the plateau, easing the amount of warming the region undergoes.
The work, which appeared in Atmospheric Chemistry and Physics in June, shows that soot pollution on and above the Himalayan-Tibetan Plateau area warms the region enough to contribute to earlier ...
Following several years of research and collaboration, physicians and engineers at Johns Hopkins and Walter Reed National Military Medical Center say they have developed a computer platform that provides rapid, real-time feedback before and during facial transplant surgery, which may someday improve face-jaw-teeth alignment between donor and recipient.
Surgeons performed the first successful transplant of facial features, including the jaw and teeth, in 2008, mainly relying on visual judgment. Since then, approximately 30 facial transplants have been done worldwide, ...
